Immunis, Inc.
PrivateLast Round
Seed Round
Jun 15, 2026
Est. Valuation
$30M
Total Funding Raised
$35.25M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Immunis, Inc. is a biotechnology company that develops multi-active biologics derived from stem cell secretomes to address age-related diseases and immune dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunis, Inc. Comparables
Compare Immunis, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Secretome Therapeutics | 84% | |
| Remedy Cell Ltd. | 76% | |
| Direct Biologics | 72% | |
Immunis, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jun 15, 2026 | ||||
| Grant | May 12, 2025 | ||||
| Series A Extension | Jan 11, 2025 | ||||
| Series A | Aug 3, 2022 |
Immunis, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A Extension, Series A |
| BOLD Capital Partners | Series A Extension |
| X PRIZE Foundation | Grant |
| Continuum Health Ventures | Series A Extension, Series A |
| LifeSpan Vision Ventures | Series A Extension |
| JLS Fund | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 15, 2026
$12M raised in Seed Round.
- Mar 5, 2026
Obtained exclusive rights for product KORA in US, Canada, EU, and EFTA.
Immunis, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immunis, Inc.'s valuation, stock price, and market status.